133 related articles for article (PubMed ID: 31250729)
21. Influence of methylenetetrahydrofolate reductase gene polymorphisms on the outcome of pediatric patients with non-Hodgkin lymphoma treated with high-dose methotrexate.
D'Angelo V; Ramaglia M; Iannotta A; Francese M; Pota E; Affinita MC; Pecoraro G; Indolfi C; Di Martino M; Di Pinto D; Buffardi S; Poggi V; Indolfi P; Casale F
Leuk Lymphoma; 2013 Dec; 54(12):2639-44. PubMed ID: 23488607
[TBL] [Abstract][Full Text] [Related]
22. Adverse drug reaction to methotrexate: pharmacogenetic origin.
Przekop PR; Tulgan H; Przekop AA; Glantz M
J Am Osteopath Assoc; 2006 Dec; 106(12):706-7. PubMed ID: 17242415
[TBL] [Abstract][Full Text] [Related]
23. The pharmacogenetics of methotrexate.
Hider SL; Bruce IN; Thomson W
Rheumatology (Oxford); 2007 Oct; 46(10):1520-4. PubMed ID: 17586865
[TBL] [Abstract][Full Text] [Related]
24. Bullous variant of acral erythema due to methotrexate.
Kuruvila S; Dalal M; Sivanesan B
Indian J Dermatol Venereol Leprol; 2006; 72(6):440-2. PubMed ID: 17179620
[TBL] [Abstract][Full Text] [Related]
25. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis.
Kumagai K; Hiyama K; Oyama T; Maeda H; Kohno N
Int J Mol Med; 2003 May; 11(5):593-600. PubMed ID: 12684695
[TBL] [Abstract][Full Text] [Related]
26. 5-Fluorouracil pharmacogenomics: still rocking after all these years?
Scartozzi M; Maccaroni E; Giampieri R; Pistelli M; Bittoni A; Del Prete M; Berardi R; Cascinu S
Pharmacogenomics; 2011 Feb; 12(2):251-65. PubMed ID: 21332317
[TBL] [Abstract][Full Text] [Related]
27. Influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia.
Erčulj N; Kotnik BF; Debeljak M; Jazbec J; Dolžan V
Leuk Lymphoma; 2012 Jun; 53(6):1096-104. PubMed ID: 22074251
[TBL] [Abstract][Full Text] [Related]
28. Subacute leukencephalopathy after low-dose intrathecal methotrexate in an adolescent heterozygous for the MTHFR C677T polymorphism.
Strunk T; Gottschalk S; Goepel W; Bucsky P; Schultz C
Med Pediatr Oncol; 2003 Jan; 40(1):48-50. PubMed ID: 12426687
[No Abstract] [Full Text] [Related]
29. Severe toxic effects of low-dose methotrexate treatment for placenta accreta in a patient with methylenetetrahydrofolate reductase mutations.
Tan Z; Liu W; Guo H; Hu K; Zhao R
J Clin Pharm Ther; 2020 Feb; 45(1):214-217. PubMed ID: 31545520
[TBL] [Abstract][Full Text] [Related]
30. [Acute toxicity of high doses of methotrexate in treatment of ALL in children: a case study].
Periáñez-Párraga L; Pérez-Rodríguez O; do Pazo-Oubiña F; Crespí-Monjo M
Farm Hosp; 2009; 33(3):172-3. PubMed ID: 19712601
[No Abstract] [Full Text] [Related]
31. Almost a tragedy: severe methotrexate toxicity in a hemodialysis patient treated for ectopic pregnancy.
Willner N; Storch S; Tadmor T; Schiff E
Eur J Clin Pharmacol; 2014 Mar; 70(3):261-3. PubMed ID: 24276413
[TBL] [Abstract][Full Text] [Related]
32. Predicting fluorouracil toxicity: can we finally do it?
Ezzeldin HH; Diasio RB
J Clin Oncol; 2008 May; 26(13):2080-2. PubMed ID: 18299611
[No Abstract] [Full Text] [Related]
33. Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia.
Tantawy AA; El-Bostany EA; Adly AA; Abou El Asrar M; El-Ghouroury EA; Abdulghaffar EE
Blood Coagul Fibrinolysis; 2010 Jan; 21(1):28-34. PubMed ID: 19923983
[TBL] [Abstract][Full Text] [Related]
34. Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Kantar M; Kosova B; Cetingul N; Gumus S; Toroslu E; Zafer N; Topcuoglu N; Aksoylar S; Cinar M; Tetik A; Eroglu Z
Leuk Lymphoma; 2009 Jun; 50(6):912-7. PubMed ID: 19391036
[TBL] [Abstract][Full Text] [Related]
35. TNF-α promoter hypomethylation is frequent in oncopediatric patients who recovered from mucositis.
Viana Filho JMC; Castro Coêlho M; Queiroz Neto JN; Souza BF; Valença AMG; Oliveira NFP
Braz Oral Res; 2024; 38():e042. PubMed ID: 38747829
[TBL] [Abstract][Full Text] [Related]
36. Methotrexate nephrotoxicity: Novel treatment, new approach.
Iqbal S; Armaghani A; Aiyer R; Kazory A
J Oncol Pharm Pract; 2013 Dec; 19(4):373-6. PubMed ID: 24255083
[TBL] [Abstract][Full Text] [Related]
37. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism.
Müller J; Kralovánszky J; Adleff V; Pap E; Németh K; Komlósi V; Kovács G
Anticancer Res; 2008; 28(5B):3051-4. PubMed ID: 19031955
[TBL] [Abstract][Full Text] [Related]
38. Genetic variants associated with methotrexate-induced mucositis in cancer treatment: A systematic review and meta-analysis.
Maagdenberg H; Oosterom N; Zanen J; Gemmati D; Windsor RE; Heil SG; Esperón P; Jabeen S; Ruiz-Argüelles GJ; Zolk O; Hoerning S; Sleurs C; Lopéz-Lopéz E; Moreno-Galván M; van den Heuvel-Eibrink MM; Maitland-van der Zee AH; Carleton BC
Crit Rev Oncol Hematol; 2021 May; 161():103312. PubMed ID: 33794308
[TBL] [Abstract][Full Text] [Related]
39. Influence of methylene tetrahydrofolate reductase polymorphisms and coadministration of antimetabolites on toxicity after high dose methotrexate.
van Kooten Niekerk PB; Schmiegelow K; Schroeder H
Eur J Haematol; 2008 Nov; 81(5):391-8. PubMed ID: 18691257
[TBL] [Abstract][Full Text] [Related]
40. Weekly oral methotrexate therapy: raise awareness of fatal dosing errors.
Prescrire Int; 2013 May; 22(138):126. PubMed ID: 23819175
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
